Results research

Concall Intelligence

Follow the Sept 2026 quarter results season by comparing what companies reported with what management said next. Search official call evidence, measurable guidance, changing outlook, operating risks, and prior commitments without treating commentary as a trading recommendation.

Open reported results

Matching calls

102

After selected filters

Transcript verified

Official transcript summaries on this page

Preliminary briefs

Presentation evidence, clearly labelled

Processing

Transcript filed or call source found

Tracked companies

Watchlist or portfolio matches

Management evidence

Generated 23 Oct, 12:08 am IST · click a summary to inspect source-linked evidence for this results quarter.

Clear filters

Company	Call and sources	Reported result	Management outlook	Evidence-led conclusion	Review
SYMBIOTEC Symbiotec Pharmalab Limited Pharma · Micro	Sep 2026 2 Oct 2026 Transcript verified Transcript PPT Recording	Result pending No matching current-quarter result row	Optimistic outlook No comparable prior call Guidance maintained	Symbiotec Pharmalab reported Q1 FY27 consolidated revenue of INR 218 crores (up 7% YoY), driven mainly by the stable steroid API business. However, consolidated net profit stood lower at INR 14 crores due to a significant operational expense drag of INR 23 crores and depreciation of INR 11 crores from recently invested new businesses (biotech CDMO and complex injectables) where commercial revenues are yet to commence. Management maintains a confident revenue and EBITDA growth Evidence summary ready
LICHSGFIN LIC Housing Finance Limited Financial Services · Mid	Sept 2026 1 Oct 2026 Transcript verified Transcript	Result pending No matching current-quarter result row	Optimistic outlook No comparable prior call Guidance maintained	LIC Housing Finance Limited reported record performance in FY 2025-26 with a loan book of Rs 320,707 crore and PAT of Rs 5,595 crore, driven by synergy across operations, cost management, and declining cost of funds. Management guided towards sustainable double-digit growth and margin protection via product diversification into LAP and LRD, while acknowledging legacy asset quality challenges and intense competition from banks. Evidence summary ready

Method: Deterministic quarterly-result score from reported growth, margin direction and operating leverage. Derived only from extracted, source-linked management evidence. Pending is shown when evidence is insufficient. Measurable claims are separated from general commentary and retain outcome status when later evidence exists. Transcript-verified summaries rank above preliminary presentation briefs and source-only call evidence. Preliminary briefs are replaced automatically when an official transcript is processed. Management outlook and colours describe extracted commentary evidence; they are not buy or sell labels.